US stock futures dip as Nvidia earnings spark little cheer
Jennifer Doudna, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold a portion of her holdings in the company. According to a recent SEC filing, Doudna sold 1,320 shares of Tempus AI's Class A common stock at a price of $90 per share, totaling $118,800. The sale comes as TEM trades near its 52-week high of $91.45, with the stock showing remarkable momentum, gaining nearly 30% in the past week alone. This transaction was executed on February 14, 2025, under a pre-established Rule 10b5-1 trading plan. Following this sale, Doudna retains ownership of 36,011 shares in the company, currently valued at approximately $3.2 million. InvestingPro analysis indicates the stock is trading above its Fair Value, with technical indicators suggesting overbought conditions. Subscribers can access 14 additional ProTips and comprehensive valuation metrics for TEM.
In other recent news, Tempus AI has been making notable strides in the healthcare technology sector. The company recently completed the acquisition of Ambry Genetics, a germline testing laboratory with over $300 million in revenue. Analysts at TD Cowen have upgraded Tempus AI's stock rating and raised the price target to $74, citing the acquisition's potential to enhance the company's product offerings and facilitate entry into new markets.
Simultaneously, Tempus AI has launched Olivia, a personal health concierge app. This innovative application centralizes patient health data from over 1,000 health systems and various health devices, providing actionable AI-driven insights. The app is designed to improve patient outcomes by allowing individuals to manage and understand their healthcare journey more effectively.
In collaboration with Genialis, Tempus AI is also working on validating new RNA-based biomarker algorithms across different cancer types. This partnership is expected to advance the development of predictive biomarkers for WEE1-targeted therapies, thereby contributing to more precise and effective cancer treatments.
These recent developments underscore Tempus AI's commitment to leveraging advanced technologies to enhance precision medicine and patient care. As these initiatives unfold, investors will likely monitor the company's progress closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.